摘要
目的:探讨脂质体介导Endostatin及IL-12基因联合治疗肝癌的可行性。方法:将已构建的Endostatin和IL-12真核表达载体给荷瘤BALB/c鼠瘤内注射,每周两次测量瘤体积。ELISA法检测肿瘤局部IL-12、IL-2、Endostatin含量,MTT法检测NK细胞杀伤活性,流式细胞仪检测肿瘤细胞凋亡情况。结果:联合治疗组肿瘤体积明显小于其它各组(P<0.05);肿瘤局部IL-12、IL-2、Endostatin的表达明显高于pVAX1空载体和生理盐水对照组(P<0.05);NK细胞杀伤率和肿瘤细胞凋亡率分别为52.0%和48.2%。结论:联合应用Endostatin和IL-12基因可有效抑制鼠肝癌的生长。
Objective： To investigate the feasibility of endostatin and interleukin-12 genes mediated by lipofectine in treatment of liver cancer. Methods： Recombinant endostatin and IL-12 eukaryotic expression vectors were used to inject intratumorly BALB/c mice bearing with hepatocarcinoma cells. The size of tumors was messured two times every week. The concentration of IL-12, IL-2, endostatin in situ of tumor was detected by ELISA, the cytotoxity activity of NK cells was detected by MTT. Apoptosis of tumor cells were detected by Flow Cytometry. Results： The size of tumors in combined treatment group was significantly smaller than that in other groups （P〈0.05）. The expression of IL-12, IL-2, endostatin in combined treatment group were significantly higher than that in pVAX1 vector and normal saline control group （P〈0.05）. Cytotoxity ratio of NK cells and apoptosis of tumor cells in combined treatment group was respectively 52.0% and 48.2%. Conclusion： Combined therapy of endostatin and interleukin-12 gene can effectively inhibit the growth of murine liver cancer.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2005年第16期951-954,共4页
Chinese Journal of Clinical Oncology
基金
国家自然科学基金(编号:30100078)
霍英东教育基金资助(编号:81035)
